Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 2
1997 4
1998 9
1999 9
2000 4
2001 13
2002 7
2003 6
2004 3
2005 8
2006 7
2007 3
2008 7
2009 9
2010 9
2011 12
2012 7
2013 7
2014 9
2015 12
2016 7
2017 11
2018 13
2019 3
2020 10
2021 3
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Results by year

Filters applied: . Clear all
Page 1
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. de Bono JS, et al. Among authors: kocak i. Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X. Lancet. 2010. PMID: 20888992 Clinical Trial.
Oligometastatic Prostate Cancer.
Navrátil J, Poprach A, Lakomý R, Kocák I, Vašina J, Krupa P, Vyzula R. Navrátil J, et al. Among authors: kocak i. Klin Onkol. 2019 Spring;32(2):97-100. doi: 10.14735/amko201997. Klin Onkol. 2019. PMID: 30995848 Review. English.
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F. Clarke N, et al. Among authors: kocak i. Lancet Oncol. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4. Lancet Oncol. 2018. PMID: 29880291 Clinical Trial.
Pleural fluid microbiota as a biomarker for malignancy and prognosis.
Kwok B, Wu BG, Kocak IF, Sulaiman I, Schluger R, Li Y, Anwer R, Goparaju C, Ryan DJ, Sagatelian M, Dreier MS, Murthy V, Rafeq S, Michaud GC, Sterman DH, Bessich JL, Pass HI, Segal LN, Tsay JJ. Kwok B, et al. Among authors: kocak if. Sci Rep. 2023 Feb 8;13(1):2229. doi: 10.1038/s41598-023-29001-4. Sci Rep. 2023. PMID: 36755121 Free PMC article.
Autosomal recessive nanophthalmos.
Altintaş AK, Acar MA, Yalvaç IS, Koçak I, Nurözler A, Duman S. Altintaş AK, et al. Among authors: kocak i. Acta Ophthalmol Scand. 1997 Jun;75(3):325-8. doi: 10.1111/j.1600-0420.1997.tb00788.x. Acta Ophthalmol Scand. 1997. PMID: 9253989 Free article.
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F, Thiery-Vuillemin A, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Kang J, Burgents J, Gresty C, Degboe A, Clarke NW. Saad F, et al. Among authors: kocak i. Lancet Oncol. 2022 Oct;23(10):1297-1307. doi: 10.1016/S1470-2045(22)00498-3. Epub 2022 Sep 2. Lancet Oncol. 2022. PMID: 36063830 Clinical Trial.
180 results